[go: up one dir, main page]

CY1121698T1 - Υγρο σκευασμα για εισπνοη που περιεχει rpl554 - Google Patents

Υγρο σκευασμα για εισπνοη που περιεχει rpl554

Info

Publication number
CY1121698T1
CY1121698T1 CY20191100622T CY191100622T CY1121698T1 CY 1121698 T1 CY1121698 T1 CY 1121698T1 CY 20191100622 T CY20191100622 T CY 20191100622T CY 191100622 T CY191100622 T CY 191100622T CY 1121698 T1 CY1121698 T1 CY 1121698T1
Authority
CY
Cyprus
Prior art keywords
preparation containing
rpl554
inhalation preparation
liquid inhalation
pharmaceutical composition
Prior art date
Application number
CY20191100622T
Other languages
English (en)
Inventor
Peter Lionel Spargo
Edward James French
Phillip A HAYWOOD
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of CY1121698T1 publication Critical patent/CY1121698T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μια υγρή φαρμακευτική σύνθεση κατάλληλη για χορήγηση με εισπνοή η οποία περιλαμβάνει ένα αραιωτικό και ένα εναιώρημα σωματιδίων 9,10-διμεθοξυ-2-(2,4,6-τριμεθυλοφαινυλιμινο)-3-(Ν-καρβαμοϋλ-2-αμινοαιθυλ)-3,4,6,7-τετραϋδρο-2Η-πυριμιδο[6,1-a]ισοκινολιν-4-όνης (RPL554) ή ενός φαρμακευτικώς αποδεκτού άλατος αυτής. Περιγράφεται επίσης μια υγρή φαρμακευτική σύνθεση σύμφωνα με την εφεύρεση για χρήση στη θεραπεία ανθρώπινου ή ζωικού οργανισμού.
CY20191100622T 2014-09-15 2019-06-18 Υγρο σκευασμα για εισπνοη που περιεχει rpl554 CY1121698T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
EP15770593.0A EP3193835B1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Publications (1)

Publication Number Publication Date
CY1121698T1 true CY1121698T1 (el) 2020-07-31

Family

ID=54196992

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20181100455T CY1120264T1 (el) 2014-09-15 2018-05-03 Υγρο σκευασμα για εισπνοη που περιεχει rpl554
CY20191100622T CY1121698T1 (el) 2014-09-15 2019-06-18 Υγρο σκευασμα για εισπνοη που περιεχει rpl554
CY20211100720T CY1124546T1 (el) 2014-09-15 2021-08-10 Υγρο σκευασμα για εισπνοη που περιεχει rpl554

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20181100455T CY1120264T1 (el) 2014-09-15 2018-05-03 Υγρο σκευασμα για εισπνοη που περιεχει rpl554

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100720T CY1124546T1 (el) 2014-09-15 2021-08-10 Υγρο σκευασμα για εισπνοη που περιεχει rpl554

Country Status (27)

Country Link
US (2) US9956171B2 (el)
EP (3) EP3494962B1 (el)
JP (2) JP6860477B2 (el)
KR (1) KR102379309B1 (el)
CN (3) CN106794157B (el)
AU (3) AU2015316592B2 (el)
CA (1) CA2959943C (el)
CY (3) CY1120264T1 (el)
DK (3) DK3494962T3 (el)
ES (3) ES2875584T3 (el)
HK (1) HK1249415B (el)
HR (3) HRP20180833T1 (el)
HU (3) HUE055527T2 (el)
IL (1) IL250895B (el)
LT (3) LT3193835T (el)
MX (1) MX2017003102A (el)
MY (1) MY196072A (el)
NO (1) NO3193835T3 (el)
PH (1) PH12017500479B1 (el)
PL (3) PL3494962T3 (el)
PT (3) PT3332767T (el)
RS (3) RS57227B1 (el)
RU (1) RU2699995C2 (el)
SG (1) SG11201701854WA (el)
SI (3) SI3193835T1 (el)
SM (3) SMT202100479T1 (el)
WO (1) WO2016042313A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
HUE055527T2 (hu) * 2014-09-15 2021-12-28 Verona Pharma Plc RPL554-t tartalmazó folyékony inhalációs készítmény
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
JP6814754B2 (ja) 2015-07-24 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害剤ペプチド
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
EP4092025B9 (en) * 2020-01-15 2024-11-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) * 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
AU2023324461A1 (en) * 2022-08-08 2025-02-06 Verona Pharma Plc Ensifentrine (rpl-554) for decreasing the frequency and/or severity of copd exacerbations
CA3263545A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc LIQUID PHARMACEUTICAL COMPOSITION
JP2025534762A (ja) * 2022-10-28 2025-10-17 江蘇恒瑞医薬股▲ふん▼有限公司 イソキノリノン系化合物を含む医薬組成物及びその調製方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
US20250073240A1 (en) * 2023-09-06 2025-03-06 Verona Pharma Plc New treatment
US20250249006A1 (en) * 2024-02-05 2025-08-07 Verona Pharma Plc Treatment
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249007A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
CA2305256C (en) 1997-10-09 2005-05-17 Schering Corporation Mometasone furoate suspensions for nebulization
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
WO2000058308A1 (en) 1999-03-31 2000-10-05 Vernalis Limited DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) * 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US7579505B2 (en) 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
BR112012032332A2 (pt) 2010-06-22 2016-11-08 Chiesi Farma Spa composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
DK2603509T3 (da) 2010-08-09 2014-09-08 Verona Pharma Plc KRYSTALLINSK FORM AF PYRIMIDIO [6,1- a] ISOQUINOLIN-4-ON-FORBINDELSE
CN103732213A (zh) * 2011-06-07 2014-04-16 帕里昂科学公司 治疗方法
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
PT2968312T (pt) 2013-03-15 2018-04-19 Verona Pharma Plc Combinação de fármacos
JP6702634B2 (ja) * 2014-03-11 2020-06-03 エルジー エレクトロニクス インコーポレイティド 無線通信システムにおいて装置対装置端末のディスカバリ信号伝送方法及び装置
PL3231444T3 (pl) 2014-05-12 2020-05-18 Verona Pharma Plc Nowe leczenie
HUE055527T2 (hu) * 2014-09-15 2021-12-28 Verona Pharma Plc RPL554-t tartalmazó folyékony inhalációs készítmény
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
EP3332767A1 (en) 2018-06-13
CN111249260B (zh) 2023-01-10
EP3332767B1 (en) 2019-03-20
LT3193835T (lt) 2018-06-11
KR102379309B1 (ko) 2022-03-28
IL250895B (en) 2019-08-29
LT3494962T (lt) 2021-07-26
CN110051627A (zh) 2019-07-26
AU2018286571A1 (en) 2019-01-24
EP3494962A1 (en) 2019-06-12
CA2959943A1 (en) 2016-03-24
SI3332767T1 (sl) 2019-07-31
PL3494962T3 (pl) 2021-12-06
NZ767296A (en) 2024-01-26
SMT202100479T1 (it) 2021-09-14
HUE038433T2 (hu) 2018-10-29
IL250895A0 (en) 2017-04-30
WO2016042313A1 (en) 2016-03-24
US10945950B2 (en) 2021-03-16
JP2019069978A (ja) 2019-05-09
HUE055527T2 (hu) 2021-12-28
PL3332767T3 (pl) 2019-10-31
US20170239178A1 (en) 2017-08-24
HK1249415B (en) 2019-11-22
CN106794157A (zh) 2017-05-31
RS62252B1 (sr) 2021-09-30
AU2015316592A1 (en) 2017-03-23
ES2730810T3 (es) 2019-11-12
JP2017528479A (ja) 2017-09-28
HRP20211035T1 (hr) 2021-09-17
HUE045303T2 (hu) 2019-12-30
ES2875584T3 (es) 2021-11-10
AU2020203081A1 (en) 2020-05-28
RS57227B1 (sr) 2018-07-31
CY1120264T1 (el) 2019-07-10
PH12017500479B1 (en) 2021-07-21
EP3193835B1 (en) 2018-03-07
SI3193835T1 (en) 2018-06-29
ES2670025T3 (es) 2018-05-29
JP6795574B2 (ja) 2020-12-02
PT3332767T (pt) 2019-06-27
BR112017005050A2 (pt) 2018-01-23
AU2018286571B2 (en) 2020-04-02
EP3193835A1 (en) 2017-07-26
HRP20180833T1 (hr) 2018-06-29
SMT201800242T1 (it) 2018-07-17
MY196072A (en) 2023-03-13
CN106794157B (zh) 2021-03-09
AU2015316592B2 (en) 2020-04-02
EP3494962B1 (en) 2021-05-26
SI3494962T1 (sl) 2021-09-30
SG11201701854WA (en) 2017-04-27
CY1124546T1 (el) 2022-07-22
DK3332767T3 (da) 2019-06-24
RU2017108432A (ru) 2018-10-17
DK3193835T3 (en) 2018-05-07
MX2017003102A (es) 2017-06-14
RU2017108432A3 (el) 2019-04-01
SMT201900340T1 (it) 2019-07-11
HRP20191122T1 (hr) 2019-09-20
PT3193835T (pt) 2018-03-27
DK3494962T3 (da) 2021-06-21
PT3494962T (pt) 2021-06-22
NO3193835T3 (el) 2018-08-04
US20180369139A1 (en) 2018-12-27
AU2020203081B2 (en) 2021-08-05
PH12017500479A1 (en) 2017-07-31
RS58897B1 (sr) 2019-08-30
CA2959943C (en) 2022-08-16
NZ729796A (en) 2024-01-26
KR20170054406A (ko) 2017-05-17
US9956171B2 (en) 2018-05-01
PL3193835T3 (pl) 2018-07-31
LT3332767T (lt) 2019-06-25
RU2699995C2 (ru) 2019-09-12
JP6860477B2 (ja) 2021-04-14
NZ767295A (en) 2024-01-26
CN111249260A (zh) 2020-06-09

Similar Documents

Publication Publication Date Title
CY1121698T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
CY1124675T1 (el) Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
UA107112C2 (uk) Активатори розчинної гуанілатциклази
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201792237A1 (ru) Фармацевтические составы
GB2558494B (en) Protein nanostructure based drug delivery system for the delivery of therapeutic agents to the anterior segment of the eye
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
EA202091139A1 (ru) Производные имидазопиридина и их применение в качестве лекарственного средства
PH12018502195A1 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
TH174318A (th) สูตรผสม
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения
MX2014008984A (es) Proceso de obtencion y composicion farmaceutica de fenofibrato capsulas como agente regulador de lipidos para su administracion oral.